Compare CLB & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLB | OMER |
|---|---|---|
| Founded | 1936 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.5M | 894.8M |
| IPO Year | 1995 | 2009 |
| Metric | CLB | OMER |
|---|---|---|
| Price | $19.47 | $11.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.50 | ★ $32.50 |
| AVG Volume (30 Days) | 361.0K | ★ 4.5M |
| Earning Date | 02-04-2026 | 11-13-2025 |
| Dividend Yield | ★ 0.21% | N/A |
| EPS Growth | ★ 25.86 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $517,501,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.33 | N/A |
| P/E Ratio | $28.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.72 | $2.95 |
| 52 Week High | $20.82 | $17.65 |
| Indicator | CLB | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 74.09 | 47.41 |
| Support Level | $18.82 | $11.85 |
| Resistance Level | $19.96 | $13.26 |
| Average True Range (ATR) | 0.64 | 1.32 |
| MACD | 0.18 | -0.46 |
| Stochastic Oscillator | 88.35 | 4.22 |
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.